New research that appeared in the journal Oncotarget has opened the door to a new way to approach the treatment of oral ulcers induced by chemotherapy. This debilitating and painful side effect of cancer treatment lowers the quality of life of patients undergoing chemotherapy, but oral mucositis remains an unmet medical need.
The study was conducted by a joint team from the Center for Research in Physics in Brazil and others from Rio de Janeiro Federal University. The lead author was Ana Chor. They sought to examine how effective an electrospun poly membrane (PLGA) was in accelerating tissue regeneration in cases of chemotherapy-triggered oral mucositis. The researchers used an animal model featuring hamsters in their study.
They found that the PLGA membranes, especially when they were used alongside healing cells from the body, had the effect of accelerating the process of recovery while also toning down inflammation. Their findings could usher in a new paradigm in the way oral ulcers are treated in patients undergoing chemotherapy to combat various cancers.
Oral ulcers manifest in a significant fraction of all patients to whom 5-Fluorouracil chemotherapy is administered. The side effect makes it hard for these patients to eat, drink or even speak. Despite how common this side effect is, there are very few treatments that can effectively address this condition. The research was aimed at exploring whether bioengineered materials could fill this treatment gap.
The researchers applied PLGA membranes to the chemotherapy-linked ulcers in a group of hamsters. Some hamsters got just the membranes while other hamsters had the membranes infused with mesenchymal cells extracted from the hamsters themselves to boost the process of healing.
The team noted that in just six days, the hamsters with PLGA membranes infused with mesenchymal cells had healed completely. Additionally, inflammation was minimal and new blood vessels were observed in the ulcerated regions. These blood vessels are pivotal during the healing process.
In contrast, the hamsters that only had PLGA membranes applied to their oral ulcers had a slower rate of healing. The membranes helped, but the lack of mesenchymal cells in the membranes denied these hamsters an element that would have boosted how quickly they healed.
A lot more research needs to be done before these promising findings from an animal study can be translated into approved treatments for humans. As bioengineered materials are further studied to establish how they can be leveraged to treat chemotherapy-induced oral ulcers, other efforts are being undertaken by companies like Soligenix Inc. (NASDAQ: SNGX) to develop effective drugs for similar conditions.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Doctors in Spain recently handled a fascinating yet terrifying case of a patient that developed brain cancer-like symptoms and…
While immunotherapy is revolutionizing cancer therapy, response rates to these novel treatments are low and some patients…
Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production…
The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage…
As July came to an end, the United States reached an undesirable milestone: exceeding the…
Scientists and public health experts are warning that climate change is accelerating the rate at which infectious…